- Home
- MRAM vs BMEA Comparison
MRAM vs BMEA Comparison
Compare MRAM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- BMEA
- Stock Information
- Founded
- MRAM 2008
- BMEA 2017
- Country
- MRAM United States
- BMEA United States
- Employees
- MRAM N/A
- BMEA N/A
- Industry
- MRAM Semiconductors
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- BMEA Health Care
- Exchange
- MRAM Nasdaq
- BMEA Nasdaq
- Market Cap
- MRAM 134.5M
- BMEA 145.0M
- IPO Year
- MRAM 2016
- BMEA 2021
- Fundamental
- Price
- MRAM $5.80
- BMEA $3.98
- Analyst Decision
- MRAM Strong Buy
- BMEA Buy
- Analyst Count
- MRAM 2
- BMEA 13
- Target Price
- MRAM $9.00
- BMEA $27.92
- AVG Volume (30 Days)
- MRAM 93.4K
- BMEA 682.9K
- Earning Date
- MRAM 02-26-2025
- BMEA 10-29-2024
- Dividend Yield
- MRAM N/A
- BMEA N/A
- EPS Growth
- MRAM N/A
- BMEA N/A
- EPS
- MRAM 0.07
- BMEA N/A
- Revenue
- MRAM $53,865,000.00
- BMEA N/A
- Revenue This Year
- MRAM N/A
- BMEA N/A
- Revenue Next Year
- MRAM $7.15
- BMEA N/A
- P/E Ratio
- MRAM $80.91
- BMEA N/A
- Revenue Growth
- MRAM N/A
- BMEA N/A
- 52 Week Low
- MRAM $4.89
- BMEA $3.61
- 52 Week High
- MRAM $9.39
- BMEA $19.89
- Technical
- Relative Strength Index (RSI)
- MRAM 35.09
- BMEA 37.96
- Support Level
- MRAM $6.11
- BMEA $4.13
- Resistance Level
- MRAM $6.30
- BMEA $4.43
- Average True Range (ATR)
- MRAM 0.23
- BMEA 0.24
- MACD
- MRAM -0.07
- BMEA 0.06
- Stochastic Oscillator
- MRAM 3.48
- BMEA 22.78
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.